AMAÇ: Doğal ve cerrahi menopozun serum lipidleri, lipoprotein- a, C-reaktif protein, homosistein, folat ve vitamin B12 düzeyleri üzerine etkisini araştırmak. GEREÇ VE YÖNTEM: Çalışmaya 126 sağlıklı kadın dahil edildi. Kadınların 20’si perimenopoz, 62’si doğal menopoz ve 44’ü cerrahi menopozda idi. Total kolesterol düzeyleri, düşük dansiteli lipoprotein-kolesterol, yüksek dansiteli lipoprotein-kolesterol, trigliserid, lipoprotein-a, C-reaktif protein, homosistein, folat ve vitamin B12 düzeyleri ölçüldü ve gruplar arası karşılaştırmalar yapıldı. BULGULAR: Doğal menopoz grubu ile perimenopozal grup arasında, total kolesterol, trigliserid, lipoprotein-a, homosistein ve folat düzeyleri bakımından anlamlı bir fark saptanmadı. Ayrıca cerrahi menopoz grubunda total kolesterol, lipoproteina, homosistein, vitamin B12 düzeyleri perimenopozal gruba göre yüksek, yüksek dansiteli lipoprotein-kolesterol düzeyi ise düşük saptanmasına rağmen bu fark istatistiksel olarak anlamlı değildi. Düşük dansiteli lipoprotein-kolesterol düzeyi doğal menopozal kadınlarda, perimenopozal kadınlara göre anlamlı olarak daha yüksekti (p
OBJECTIVE: To investigate the influence of both natural and surgical menopause on serum concentrations of lipids, lipoprotein-a, C-reactive protein, homocysteine, folate and vitamin B12 levels. STUDY DESIGN: The study included 126 healthy women: 20 perimenopausal, 62 natural menopausal, and 44 surgical menopausal women. The serum levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, lipoprotein-a, C-reactive protein, homocysteine, folate and vitamin B12 levels were measured, and comparisons were made between the groups. RESULTS: The plasma levels of total cholesterol, triglyceride, lipoprotein-a, homocysteine and folate were non-significantly higher in natural menopause group compared to perimenopause group. Also plasma total cholesterol, lipoprotein-a, homocysteine, vitamin B12 levels were higher and high-density lipoprotein cholesterol level was lower in surgical menopause group compared to perimenopause group, the difference was not significant. The plasma level of low-density lipoprotein cholesterol was significantly higher in natural menopausal women than perimenopausal women (p<0.05). Surgical menopausal women had higher but non-significant low-density lipoprotein cholesterol levels than perimenopausal women. There was a negative correlation between age and high-density lipoprotein cholesterol in natural menopause group, and there was a positive correlation between age and homocysteine in natural and surgical menopausal groups (p<0.05). CONCLUSION: We did not find any significant difference in studied cardiovascular risk markers, folate and vitamin B12 levels in perimenopausal and postmenopausal women except low-density lipoprotein cholesterol levels.
1. Eaker ED, Chesebro JH, Sacks FM. et al. Cardiovascular disease in women. Circulation 1993;88:1999-2009.
2. Cummings SR, Black DM, Rubin SM. Lifetime risk of hip Colles’, or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989;149: 2445-8.
3. Gordon T, Kannel WB, Hjortland MC. et al. Menopause and coronary heart disease, the Framingham study. Ann Intern Med 1978;89:157-61.
4. Lobo RA. Surgical menopause and cardiovascular risks. Menopause 2007;14:562-66.
5. Miller NE, Thelle DS, Forde OH. et al. The Tromso heartstudy. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1977;1:965-8.
6. Gordon T, Castelli WP, Hjortland MC. et al. High density lipoprotein as a protective factor againist coronary heart disease. The Framingham study. Am J Med 1977;62:707-14.
7. de Aloysio D, Gambacciani M, Meschia M. et al. The effect of menopause on blood lipid and lipoprotein levels. The Icarus Study Group. Atherosclerosis 1999;147:147-53.
8. Bush TL, Fried LP, Barrett-Connor E. Cholesterol, lipop - ro teins and coronary heart disease in women. Clin Chem 1988;34:60-70.
9. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a) and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283:1845-52.
10. Graham IM, Daly LE, Refsum HM. et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277: 1775-81.
11. Marchesoni D, Driul L, Plaino L, et al. Menopause rather than estrogen modifies plasma homocysteine levels. Int J Gynaecol Obstet 2003;81:293-7.
12. Christodoulakos G, Panoulis C, Rizos D. et al. Homocysteine and folate levels in postmenopausal women. Maturitas 2001;39:161-7.
13. Andersson A, Brattstrom L, Israelsson B. et al. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992;22:79-87.
14. Bruschi F, Daguati R, Parazzini F. et al. Age, menopausal status and homocysteine levels in women around menopause. Eur J Obstet Gynecol Reprod Biol 2005; 120:195-7.
15. Eidelman RS, Lamas GA, Hennekens CH. Aspirin, postmenopausal hormones and C-reactive protein. Arch Intern Med 2002;162:480-1.
16. National American Menopause Society. Menopause Practice: A Clinician’s Guide. Available at: http:// www.menopause.org/edumaterials/cliniciansguide/cliniciansguide. htm. Accessed 17 December 2005.
17. Howard BV, Kuller L, Langer R. et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. Circulation 2005;111:1462-70.
18. Carr MC, Kim KH, Zambon A. et al. Changes in LDL density across the menopausal transition. J Investig Med. 2000;48:245-50.
19. Hall G, Collins A, Csemiczky G. et al. Lipoproteins and BMI: a comparison between women during transition to menopause and regularly menstruating healthy women. Maturitas 2002;41:177-85.
20. Azizi F, Ainy E. Coronary heart disease risk factors and menopause: a study in 1980 Tehranian women, the Tehran Lipid and Glucose Study. Climacteric 2003;6:330-6.
21. Stampfer MJ, Colditz GA, Willett WC. Menopause and heart disease: a review. Ann NY Acad Sci 1990;592:286-94.
22. Wolf PH, Madans JH, Finucane FF. et al. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991;164:489-94.
23. Atsma F, Bartelink ML, Grobbee DE. et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265-79.
24. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861-7.
25. van Beresteijn ECH, Korevaar JC, Huijbregts PCW. et al. Perimenopausal increase in serum cholesterol: A 10-year longitudinal study. Am J Epidemiol 1993;137:383-92.
26. Campos PR, McNamara JR, Wilson PWF. et al. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1998;67:30-5.
27. Matthews KA, Meilahn E, Kuller LH. et al. Menopause and risk factors for coronary heart disease. N Engl J Med 1989;321:641-6.
28. Sohn E, Daggy BP, Arjmandi BH. Ovariectomized hamster: A potential model of postmenopausal hypercholesterolemia. J Nutr Biochem 1999;10:660-3.
29. Downs JR, Clearfield M, Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosc lerosis Prevention Study. JAMA 1998;279:1615-22.
30. Blake GJ, Otvos JD, Rifai N. et al. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002; 106:1930-7.
31. Wakatsuki A, Ikenoue N, Sagara Y. Effects of estrogen on susceptibility to oxidation of low-density and high-density lipoprotein in postmenopausal women. Maturitas 1998; 28:229-34.
32. Verhoeven MO, van der Mooren MJ, Teerlink T. et al. The influence of physiological and surgical menopause on coronary heart disease risk markers. Menopause 2009; 16:37-49.
33. Do KA, Green A, Guthrie JR. et al. Longitudinal study of risk factors for coronary heart disease across the menopausal transition. Am J Epidemiol. 2000;151:584-93.
34. Palan PR, Connell K, Ramirez E. et al. Effects of menopause and hormone replacement therapy on serum levels of coenzyme Q10 and other lipid-soluble antioxidants. Biofactors 2005;25:61-6.
35. Pasquali R, Casimirri F, Labate AM. et al. The VMH Collaborative Group. Body weight, fat distribution and the menopausal status in women. Int J Obes Relat Metab Disord 1994;18:614-21.
36. Matthews KA, Abrams B, Crawford S. et al. Body mass index in mid-life women: relative influence of menopau - se, hormone use, and ethnicity. Int J Obes Relat Metab Disord 2001;25:863-73.
37. Derby CA, Crawford SL, Pasternak RC. et al. Lipid changes during the menopause transition in relation to age and weight: the Study of Women’s Health across the Nation. Am J Epidemiol. 2009;169:1352-61.
38. Wing RR, Matthews KA, Kuller LH. et al. Weight gain at the time of menopause. Arch Intern Med 1991;151:97-102.
39. Rosengren A, Wilhelmsen L, Eriksson E. et al. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ 1990;301:1248-51.
40. Jovicic A, Ivanisevic V, Ivanovic I. Lipoprotein(a) in patients with carotid atherosclerosis and ischemic cerebrovascular disorders. Atherosclerosis 1993;98:59-65.
41. Kim CJ, Ryu WS, Kwak JW, Park CT, Ryoo UH. Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy. Arch Intern Med 1996;156:500-4.
42. Bruschi F, Meschia M, Soma M, et al. Lipoprotein(a) and other lipids after oophorectomy and estrogen replacement therapy. Obstet Gynecol 1996;88:950-4.
43. Moustapha A, Robinson K. Homocysteine: an emerging age-related cardiovascular risk factor. Geriatrics 1999; 54:49-51.
44. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
45. Mijatovic V, Kenemans P, Netelenbos C. et al. Postmenopausal oral 17 beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril 1998;69:876-82.
46. Clarke R. Prevention of vitamin B-12 deficiency in old age. Am J Clin Nutr 2001;73:151-2.
47. Post MS, van der Mooren MJ, Stehouwer CDA. et al. Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: A randomised, placebo-controlled trial. Thromb Haemost 2002;88:605-10.
48. Backes JM, Howard PA, Moriarty PM. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother 2004;38:110-8.
49. Stefánska A, Sypniewskay G, Senterkiewicz L. Inflammatory markers and cardiovascular risk in healthy polish women across the menopausal transition. Clin Chem 2005;51:1893-95.
50. Zhou LJ, Lin SQ, Shen Y, et al. Serum lipid profile changes during the menopausal transition in Chinese women: a community-based cohort study. Menopause 2010;17:997-1003.
51. Chu MC, Rath KM, Huie J, et al. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk. Hum Reprod 2003;18:1570-3.
52. Berg G, Mesch V, Boero L. et al. Lipid and lipoprotein profile in menopausal transition. Effects of hormones, age and fat distribution. Horm Metab Res 2004;36:215-20.